Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Lutetium (177Lu) Zadavotide Guraxetan
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : CURIUM US LLC
Deal Size : Undisclosed
Deal Type : Acquisition
Curium Completes Monrol Acquisition To Expand Lutetium-177 Capacity
Details : The acquisition enhances Curium’s manufacturing of Lutetium-177 to meet the growing demand for isotope around the world. Curium’s Lu-177 (Lutetium-177 PSMA-I&T) is being evaluated for Prostate Cancer.
Product Name : Curium Lu-177
Product Type : Radiolabelled Compounds
Upfront Cash : Undisclosed
March 28, 2025
Lead Product(s) : Lutetium (177Lu) Zadavotide Guraxetan
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : CURIUM US LLC
Deal Size : Undisclosed
Deal Type : Acquisition
Monrol and FutureChem Announced a Clinical Supply Partnership
Details : 177Lu-FC705 belongs to the 2nd generation of albumin binders introduced drugs. Its hydrophilicity is higher than that of other compounds, and has low nonspecific binding.
Product Name : 177-Lu FC705
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
November 18, 2022